EP1650301B8
(en)
*
|
2003-07-31 |
2009-11-18 |
HONDA MOTOR CO., Ltd. |
Genes that confer regeneration ability to plants, and uses thereof
|
KR20090114443A
(ko)
|
2007-02-09 |
2009-11-03 |
제넨테크, 인크. |
항-Robo4 항체 및 그의 용도
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
MX2010007962A
(es)
|
2007-11-27 |
2010-11-10 |
Medicago Inc |
Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina.
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
EA034733B1
(ru)
|
2008-01-21 |
2020-03-13 |
Медикаго Инк. |
Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
|
EP2271770B1
(en)
*
|
2008-03-31 |
2018-08-22 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing asthma
|
WO2010078376A2
(en)
|
2008-12-30 |
2010-07-08 |
Ventana Medical Systems, Inc. |
Fc-specific polymer-conjugated antibodies and their diagnostic use
|
AU2010226453B2
(en)
|
2009-03-20 |
2013-11-21 |
Genentech, Inc. |
Bispecific anti-HER antibodies
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
NO2445928T3
(pt)
|
2009-06-24 |
2018-08-25 |
|
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AU2010296018B2
(en)
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
SG2014011340A
(en)
|
2009-12-21 |
2014-07-30 |
Genentech Inc |
Antibody formulation
|
EP2536748B1
(en)
|
2010-02-18 |
2014-08-20 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
NZ602040A
(en)
|
2010-03-24 |
2014-12-24 |
Genentech Inc |
Anti-lrp6 antibodies
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
AR082017A1
(es)
|
2010-06-18 |
2012-11-07 |
Genentech Inc |
Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
WO2012006503A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
AR082163A1
(es)
|
2010-07-15 |
2012-11-14 |
Hoffmann La Roche |
Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
WO2012020038A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
KR101673653B1
(ko)
|
2010-08-13 |
2016-11-08 |
로슈 글리카트 아게 |
항-fap 항체 및 이의 사용 방법
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
MX340555B
(es)
|
2010-08-25 |
2016-07-14 |
F Hoffmann-La Roche Ag * |
Anticuerpos contra il-18r1 y usos de los mismos.
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EA201390669A1
(ru)
|
2010-11-10 |
2013-11-29 |
Дженентек, Инк. |
Способы и композиции для иммунотерапии заболеваний нервной системы
|
EP2652498B1
(en)
|
2010-12-16 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Diagnosis and treatments relating to th2 inhibition
|
CA2819269A1
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CN103282054A
(zh)
|
2011-01-03 |
2013-09-04 |
弗·哈夫曼-拉罗切有限公司 |
抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
|
EP2672999A2
(en)
|
2011-02-10 |
2013-12-18 |
Roche Glycart AG |
Improved immunotherapy
|
KR101667096B1
(ko)
|
2011-02-10 |
2016-10-18 |
로슈 글리카트 아게 |
돌연변이 인터루킨-2 폴리펩티드
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
KR101638224B1
(ko)
|
2011-02-28 |
2016-07-08 |
에프. 호프만-라 로슈 아게 |
항원 결합 단백질
|
RS57895B1
(sr)
|
2011-03-29 |
2019-01-31 |
Roche Glycart Ag |
Fc varijante antitela
|
JP2014516511A
(ja)
|
2011-04-07 |
2014-07-17 |
ジェネンテック, インコーポレイテッド |
抗fgfr4抗体及び使用方法
|
BR112013026423A2
(pt)
|
2011-04-20 |
2016-11-29 |
Roche Glycart Ag |
método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
ES2567276T3
(es)
|
2011-05-12 |
2016-04-21 |
Genentech, Inc. |
Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
|
PT2710035T
(pt)
|
2011-05-16 |
2017-06-05 |
Hoffmann La Roche |
Agonistas do fgfr1 e métodos de utilização
|
WO2012171996A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
CA2835772C
(en)
|
2011-06-22 |
2020-12-01 |
F. Hoffmann-La Roche Ag |
Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
CA2844538C
(en)
|
2011-08-23 |
2020-09-22 |
Roche Glycart Ag |
Bispecific antigen binding molecules
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
JP2014534806A
(ja)
|
2011-08-23 |
2014-12-25 |
ロシュ グリクアート アーゲー |
抗mcsp抗体
|
PL2748201T3
(pl)
|
2011-08-23 |
2018-04-30 |
Roche Glycart Ag |
Aktywujące komórki t dwuswoiste cząsteczki wiążące antygen
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
CN103781801B
(zh)
|
2011-08-23 |
2018-02-09 |
罗切格利卡特公司 |
包含两个Fab片段的无Fc的抗体及使用方法
|
BR112014005720A2
(pt)
|
2011-09-15 |
2017-12-12 |
Genentech Inc |
método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
|
CA2845147A1
(en)
|
2011-09-23 |
2013-03-28 |
Roche Glycart Ag |
Bispecific anti-egfr/anti igf-1r antibodies
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
AR088322A1
(es)
|
2011-10-14 |
2014-05-28 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
CN103998027A
(zh)
|
2011-10-15 |
2014-08-20 |
霍夫曼-拉罗奇有限公司 |
用于治疗癌症的scd1拮抗剂
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
RU2014120577A
(ru)
|
2011-10-26 |
2015-12-10 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Моноклональное антитело cd44 для лечения b-клеточной хронической лимфоцитарной лейкемии и других гематологических злокачественных заболеваний
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
PT3091029T
(pt)
|
2011-10-31 |
2023-02-03 |
Hoffmann La Roche |
Formulações de anticorpos anti-il13
|
JP2014533700A
(ja)
|
2011-11-21 |
2014-12-15 |
ジェネンテック, インコーポレイテッド |
抗c−MET抗体の精製
|
SG11201402711SA
(en)
|
2011-11-29 |
2014-06-27 |
Genentech Inc |
Compositions and methods for prostate cancer analysis
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
KR102184059B1
(ko)
|
2011-12-22 |
2020-11-30 |
에프. 호프만-라 로슈 아게 |
발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도
|
CN104011080B
(zh)
|
2011-12-22 |
2017-10-20 |
弗·哈夫曼-拉罗切有限公司 |
用于真核细胞的全长抗体展示系统及其用途
|
CN113896787A
(zh)
|
2011-12-22 |
2022-01-07 |
弗·哈夫曼-拉罗切有限公司 |
表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
EP2804630B1
(en)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Methods of using fgf19 modulators
|
KR20140116490A
(ko)
|
2012-01-18 |
2014-10-02 |
제넨테크, 인크. |
항-lrp5 항체 및 사용 방법
|
KR20140127854A
(ko)
|
2012-02-10 |
2014-11-04 |
제넨테크, 인크. |
단일-쇄 항체 및 다른 이종다량체
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
WO2013120929A1
(en)
|
2012-02-15 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
CN104159613B
(zh)
|
2012-03-08 |
2016-11-23 |
霍夫曼-拉罗奇有限公司 |
Abeta抗体制剂
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
EP2831119A1
(en)
|
2012-03-28 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Anti-hcmv idiotypic antibodies and uses thereof
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
CN114107352A
(zh)
|
2012-04-17 |
2022-03-01 |
弗·哈夫曼-拉罗切有限公司 |
使用修饰的核酸表达多肽的方法
|
EP2844300B1
(en)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
KR101843614B1
(ko)
|
2012-05-23 |
2018-03-29 |
제넨테크, 인크. |
치료제의 선택 방법
|
JP2015530867A
(ja)
|
2012-06-15 |
2015-10-29 |
ジェネンテック, インコーポレイテッド |
抗pcsk9抗体、製剤、投薬、及び使用方法
|
CA2877363A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
|
CN104395340B9
(zh)
|
2012-06-27 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
包含至少两个不同靶向实体的定制选择性和多特异性治疗分子的方法及其用途
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合している抗原−抗体結合体
|
WO2014006123A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
KR20150023938A
(ko)
|
2012-07-04 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
항-테오필린 항체 및 이의 사용 방법
|
PL2870247T3
(pl)
|
2012-07-05 |
2019-10-31 |
Hoffmann La Roche |
Układ ekspresji i wydzielania
|
MX2015000357A
(es)
|
2012-07-09 |
2015-05-12 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd22.
|
SG11201500096YA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti - cd79b antibodies
|
AU2013288931A1
(en)
|
2012-07-09 |
2014-12-11 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD22 antibodies
|
MA37840B1
(fr)
|
2012-07-09 |
2020-05-29 |
Genentech Inc |
Immunoconjugués comprenant des anticorps anti-cd79b
|
CN104428315B
(zh)
|
2012-07-13 |
2017-09-29 |
罗氏格黎卡特股份公司 |
双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
|
CN104508132B
(zh)
|
2012-08-02 |
2017-09-15 |
弗·哈夫曼-拉罗切有限公司 |
用于产生作为与惰性免疫球蛋白Fc区Fc融合的可溶FcR的方法及其用途
|
CA2872195A1
(en)
|
2012-08-07 |
2014-02-13 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
SG11201408526SA
(en)
|
2012-08-08 |
2015-03-30 |
Roche Glycart Ag |
Interleukin-10 fusion proteins and uses thereof
|
BR112015002790A2
(pt)
|
2012-08-09 |
2017-08-08 |
Roche Glycart Ag |
anticorpos asgpr e usos dos mesmos.
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
CA2879768A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
PE20150956A1
(es)
|
2012-11-08 |
2015-06-20 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3
|
CN104968367B
(zh)
|
2012-11-13 |
2018-04-13 |
弗·哈夫曼-拉罗切有限公司 |
抗血凝素抗体和使用方法
|
WO2014096015A1
(en)
|
2012-12-21 |
2014-06-26 |
F. Hoffmann-La Roche Ag |
Disulfide-linked multivalent mhc class i comprising multi-function proteins
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
WO2014131715A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
JP6499087B2
(ja)
|
2013-02-26 |
2019-04-10 |
ロシュ グリクアート アーゲー |
二重特異性t細胞活性化抗原結合分子
|
US20140242080A1
(en)
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
HUE047925T2
(hu)
|
2013-02-26 |
2020-05-28 |
Roche Glycart Ag |
Bispecifikus, T-sejt-aktiváló, CD3- és CEA-specifikus antigénkötõ molekulák
|
EP2968467B1
(en)
|
2013-03-13 |
2020-06-03 |
F.Hoffmann-La Roche Ag |
Formulations with reduced oxidation
|
RU2019120404A
(ru)
|
2013-03-13 |
2019-08-06 |
Дженентек, Инк. |
Составы антител
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
RU2707092C2
(ru)
|
2013-03-13 |
2019-11-22 |
Дженентек, Инк. |
Составы со сниженным окислением
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
SG11201507037XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Anti-b7-h4 antibodies and immunoconjugates
|
WO2014145016A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
EP3712252A1
(en)
|
2013-03-15 |
2020-09-23 |
F. Hoffmann-La Roche AG |
Cell culture compositions with antioxidants and methods for polypeptide production
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
TW201522374A
(zh)
|
2013-03-15 |
2015-06-16 |
Genentech Inc |
抗crth2抗體及使用方法
|
US9441035B2
(en)
|
2013-03-15 |
2016-09-13 |
Genentech, Inc. |
Cell culture media and methods of antibody production
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
WO2014169076A1
(en)
|
2013-04-09 |
2014-10-16 |
Annexon,,Inc. |
Methods of treatment for neuromyelitis optica
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2014177461A1
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
SG11201508911PA
(en)
|
2013-04-29 |
2015-11-27 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
WO2014189973A2
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
EP3019523A4
(en)
|
2013-07-09 |
2016-12-28 |
Annexon Inc |
METHODS OF TREATING ALZHEIMER'S DISEASE AND HUNTINGTON'S DISEASE
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
EP2832854A1
(en)
|
2013-08-02 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
|
SG11201601005XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
WO2015042108A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
US10414818B2
(en)
|
2013-09-27 |
2019-09-17 |
Roche Diagnostics Operations, Inc. |
Thermus thermophilus SlyD FKBP domain specific antibodies
|
EP3626742A1
(en)
|
2013-09-27 |
2020-03-25 |
F. Hoffmann-La Roche AG |
Anti-pdl1 antibody formulations
|
CN105814078A
(zh)
|
2013-10-11 |
2016-07-27 |
豪夫迈·罗氏有限公司 |
Nsp4抑制剂及其使用方法
|
KR20160044060A
(ko)
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
다중특이적 도메인 교환된 통상의 가변 경쇄 항체
|
MX2016004802A
(es)
|
2013-10-18 |
2016-07-18 |
Genentech Inc |
Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
|
RU2016119425A
(ru)
|
2013-10-23 |
2017-11-28 |
Дженентек, Инк. |
Способы диагностики и лечения эозинофильных заболеваний
|
CN105940113A
(zh)
|
2013-11-13 |
2016-09-14 |
酵活有限公司 |
靶向egfr和/或her2的单价抗原结合构建体及其用途
|
CN111499742A
(zh)
|
2013-11-21 |
2020-08-07 |
豪夫迈·罗氏有限公司 |
抗-α-突触核蛋白抗体及使用方法
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
CN104711260B
(zh)
*
|
2013-12-13 |
2017-07-07 |
华中农业大学 |
水稻缺氮后恢复供氮特异诱导表达的启动子y8a及应用
|
WO2015095212A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
CN105934253A
(zh)
|
2013-12-17 |
2016-09-07 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
CN106029087A
(zh)
|
2013-12-20 |
2016-10-12 |
印第安纳大学研究及科技有限公司 |
脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
|
PL3083680T3
(pl)
|
2013-12-20 |
2020-06-29 |
F. Hoffmann-La Roche Ag |
Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
KR102278429B1
(ko)
|
2014-01-03 |
2021-07-16 |
에프. 호프만-라 로슈 아게 |
공유 연결된 폴리펩티드 독소-항체 콘쥬게이트
|
MX2016008189A
(es)
|
2014-01-03 |
2016-09-29 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
EP3092251B1
(en)
|
2014-01-06 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Monovalent blood brain barrier shuttle modules
|
CN105899534B
(zh)
|
2014-01-15 |
2020-01-07 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
SG11201605903SA
(en)
|
2014-01-24 |
2016-08-30 |
Genentech Inc |
Methods of using anti-steap1 antibodies and immunoconjugates
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
MX370283B
(es)
|
2014-02-06 |
2019-12-09 |
Hoffmann La Roche |
Proteinas de fusion de interleucina-2 y usos de las mismas.
|
ES2873248T3
(es)
|
2014-02-08 |
2021-11-03 |
Hoffmann La Roche |
Métodos para tratar la enfermedad de Alzheimer
|
MY179105A
(en)
|
2014-02-08 |
2020-10-28 |
Genentech Inc |
Methods of treating alzheimer's disease
|
RS57608B1
(sr)
|
2014-02-12 |
2018-11-30 |
Hoffmann La Roche |
Anti-jagged1 antitela i načini primene
|
KR20160124165A
(ko)
|
2014-02-21 |
2016-10-26 |
제넨테크, 인크. |
항-il-13/il-17 이중특이적 항체 및 그의 용도
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
CA2943357C
(en)
|
2014-03-25 |
2023-06-27 |
Genentech, Inc. |
Methods of preparing a poloxamer for use in cell culture medium
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
WO2015150446A1
(en)
|
2014-04-02 |
2015-10-08 |
F. Hoffmann-La Roche Ag |
Method for detecting multispecific antibody light chain mispairing
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
MX2016016233A
(es)
|
2014-06-11 |
2017-03-31 |
Genentech Inc |
Anticuerpos anti-lgr5 y sus usos.
|
CA2947504A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
CA2954868C
(en)
|
2014-07-11 |
2023-08-29 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
CA2951599A1
(en)
|
2014-08-04 |
2016-02-11 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
CA2955086A1
(en)
|
2014-08-08 |
2016-02-11 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
JP6622293B2
(ja)
|
2014-09-12 |
2019-12-18 |
ジェネンテック, インコーポレイテッド |
アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
SG10201809668TA
(en)
|
2014-09-12 |
2018-11-29 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
MX2017003121A
(es)
|
2014-09-15 |
2017-08-02 |
Genentech Inc |
Formulaciones de anticuerpos.
|
RU2727663C2
(ru)
|
2014-09-17 |
2020-07-22 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
|
AU2015320678B2
(en)
|
2014-09-23 |
2021-07-22 |
Genentech, Inc. |
Method of using anti-CD79b immunoconjugates
|
CN107074938A
(zh)
|
2014-10-16 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
抗‑α‑突触核蛋白抗体和使用方法
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
KR20170086540A
(ko)
|
2014-11-03 |
2017-07-26 |
제넨테크, 인크. |
T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
|
SG10202008810QA
(en)
|
2014-11-05 |
2020-10-29 |
Annexon Inc |
Humanized anti-complement factor c1q antibodies and uses thereof
|
MX2017005148A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
EP3552488A1
(en)
|
2014-11-10 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Animal model for nephropathy and agents for treating the same
|
US10093730B2
(en)
|
2014-11-10 |
2018-10-09 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
CR20170194A
(es)
|
2014-11-14 |
2017-07-10 |
Hoffmann La Roche |
Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
|
CN106999583A
(zh)
|
2014-11-17 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
MX2017006610A
(es)
|
2014-11-20 |
2017-09-29 |
Hoffmann La Roche |
Terapia combinada de moleculas de union a antigeno biespecificas activadoras de celulas t y antagonistas de union de eje de pd-1.
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
SI3227336T1
(sl)
|
2014-12-05 |
2019-10-30 |
Hoffmann La Roche |
Protitelesa proti CD79b in postopki uporabe
|
JP2018502840A
(ja)
|
2014-12-10 |
2018-02-01 |
ジェネンテック, インコーポレイテッド |
血液脳関門受容体抗体及び使用方法
|
CA2966287A1
(en)
|
2014-12-17 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Novel methods for enzyme mediated polypeptide conjugation using sortase
|
WO2016096788A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Assay and method for determining cdc eliciting antibodies
|
TW201809008A
(zh)
|
2014-12-19 |
2018-03-16 |
日商中外製藥股份有限公司 |
抗c5抗體及使用方法
|
US20180016327A1
(en)
|
2015-01-22 |
2018-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
A Combination of Two or More Anti-C5 Antibodies and Methods of Use
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EA201791754A1
(ru)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
KR20170127011A
(ko)
|
2015-03-16 |
2017-11-20 |
제넨테크, 인크. |
Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
EP3991748A3
(en)
|
2015-04-07 |
2022-08-24 |
Alector LLC |
Anti-sortilin antibodies and methods of use thereof
|
US20180105596A1
(en)
|
2015-04-17 |
2018-04-19 |
Elsalys Biotech |
Anti-tyro3 antibodies and uses thereof
|
JP6815331B2
(ja)
|
2015-04-21 |
2021-01-20 |
ジェネンテック, インコーポレイテッド |
前立腺がんの分析のための組成物及び方法
|
JP7044553B2
(ja)
|
2015-04-24 |
2022-03-30 |
ジェネンテック, インコーポレイテッド |
結合ポリペプチドを含む細菌を特定する方法
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
JP6963508B2
(ja)
|
2015-05-11 |
2021-11-10 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
KR20180013881A
(ko)
|
2015-05-29 |
2018-02-07 |
제넨테크, 인크. |
암에서의 pd-l1 프로모터 메틸화
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
EP3303386A1
(en)
|
2015-06-05 |
2018-04-11 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
EP3307771A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
CN108064246A
(zh)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
抗体和免疫结合物
|
EP4299073A3
(en)
|
2015-06-16 |
2024-03-27 |
F. Hoffmann-La Roche AG |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック, インコーポレイテッド |
抗cd3抗体及び使用方法
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
WO2016205531A2
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
JP6619460B2
(ja)
|
2015-06-24 |
2019-12-11 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ヒト化抗タウ(pS422)抗体及び使用法
|
EP4074730A1
(en)
|
2015-06-24 |
2022-10-19 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies with tailored affinity
|
CA3162816A1
(en)
|
2015-06-29 |
2017-01-05 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
EP3313885A1
(en)
|
2015-06-29 |
2018-05-02 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody for use in organ transplantation
|
TR201816369T4
(tr)
|
2015-07-28 |
2018-11-21 |
Forschungszentrum Borstel Leibniz Lungenzentrum |
Endotoksin tayinine yönelik iyileştirilmiş bakteriyel endotoksin testi.
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
EP3341411A1
(en)
|
2015-08-28 |
2018-07-04 |
Alector LLC |
Anti-siglec-7 antibodies and methods of use thereof
|
KR20230079500A
(ko)
|
2015-09-18 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8에 결합하는 항체 및 그의 사용
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
PE20181363A1
(es)
|
2015-09-23 |
2018-08-27 |
Genentech Inc |
Variantes optimizadas de anticuerpos anti-vegf
|
BR112018005931A2
(pt)
|
2015-09-24 |
2018-10-09 |
Abvitro Llc |
composições de anticorpo para hiv e métodos de uso
|
EP3353201B1
(en)
|
2015-09-25 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
|
WO2017050866A1
(en)
|
2015-09-25 |
2017-03-30 |
F. Hoffmann-La Roche Ag |
Novel soluble sortase a
|
WO2017050874A1
(en)
|
2015-09-25 |
2017-03-30 |
F. Hoffmann-La Roche Ag |
Process for producing thioesters employing a sortase a
|
CN108026560A
(zh)
|
2015-09-25 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
在低共熔溶剂中使用分选酶的转酰胺反应
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
SG10202008325XA
(en)
|
2015-10-02 |
2020-09-29 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
CR20180163A
(es)
|
2015-10-02 |
2018-05-25 |
Hoffmann La Roche |
Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
CN108026179A
(zh)
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
IL257858B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Antibodies against pd1 and methods of their use
|
AR106199A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas activadoras de células t
|
PE20180484A1
(es)
|
2015-10-02 |
2018-03-07 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
NZ741067A
(en)
|
2015-10-02 |
2023-07-28 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
EP3359569A2
(en)
|
2015-10-06 |
2018-08-15 |
Alector LLC |
Anti-trem2 antibodies and methods of use thereof
|
CA2992900A1
(en)
|
2015-10-07 |
2017-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies with tetravalency for a costimulatory tnf receptor
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
AU2016343987B2
(en)
|
2015-10-29 |
2023-11-23 |
Alector Llc |
Anti-Siglec-9 antibodies and methods of use thereof
|
CN108350066B
(zh)
|
2015-10-29 |
2022-04-15 |
豪夫迈·罗氏有限公司 |
抗变体Fc区抗体及使用方法
|
MX2018004509A
(es)
|
2015-10-30 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso de los mismos.
|
ES2904553T3
(es)
|
2015-10-30 |
2022-04-05 |
Hoffmann La Roche |
Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
EP3371217A1
(en)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Methods of screening for multispecific antibodies
|
SG11201610782YA
(en)
|
2015-12-18 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
AU2016381694A1
(en)
|
2015-12-30 |
2018-07-05 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
CN108472379B
(zh)
|
2015-12-30 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
CN114113625A
(zh)
|
2016-01-20 |
2022-03-01 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
WO2017152102A2
(en)
|
2016-03-04 |
2017-09-08 |
Alector Llc |
Anti-trem1 antibodies and methods of use thereof
|
WO2017156032A1
(en)
|
2016-03-07 |
2017-09-14 |
Charlestonpharma, Llc |
Anti-nucleolin antibodies
|
US11767362B1
(en)
|
2016-03-15 |
2023-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
CA3012422A1
(en)
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
CN109072212B
(zh)
|
2016-03-30 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
改善的分选酶
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
CN109071635B
(zh)
|
2016-05-02 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Contorsbody-单链靶标结合物
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
CA3025995C
(en)
|
2016-06-06 |
2023-08-08 |
F. Hoffmann-La Roche Ag |
Fusion proteins for ophthalmology with increased eye retention
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
WO2017223405A1
(en)
|
2016-06-24 |
2017-12-28 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
KR102591955B1
(ko)
|
2016-07-29 |
2023-10-19 |
추가이 세이야쿠 가부시키가이샤 |
증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
|
WO2018025982A1
(ja)
|
2016-08-05 |
2018-02-08 |
中外製薬株式会社 |
Il-8関連疾患の治療用又は予防用組成物
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
WO2018047154A1
(en)
|
2016-09-07 |
2018-03-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-nkp46 antibodies and therapeutic use of same
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
RS64550B1
(sr)
|
2016-09-23 |
2023-09-29 |
Hoffmann La Roche |
Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
|
JP7022123B2
(ja)
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd3に対する二重特異性抗体
|
WO2018065501A1
(en)
|
2016-10-05 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Methods for preparing antibody drug conjugates
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
CN110023334B
(zh)
|
2016-11-21 |
2023-11-14 |
科雅博有限责任公司 |
抗gp73抗体和免疫偶联物
|
KR20240035636A
(ko)
|
2016-12-07 |
2024-03-15 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
CR20230163A
(es)
|
2016-12-07 |
2023-07-06 |
Genentech Inc |
ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
|
CN117752798A
(zh)
|
2016-12-19 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
ES2847973T3
(es)
|
2016-12-20 |
2021-08-04 |
Hoffmann La Roche |
Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137)
|
JP6850351B2
(ja)
|
2016-12-21 |
2021-03-31 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗体のインビトロ糖鎖工学
|
CA3043158A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
CN110088292A
(zh)
|
2016-12-21 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
TW201829469A
(zh)
|
2017-01-03 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
包含抗4-1bb純系20h4.9之雙特異性抗原結合分子
|
AU2018211064A1
(en)
|
2017-01-18 |
2019-09-05 |
Genentech, Inc. |
Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
|
CN110494453B
(zh)
|
2017-02-10 |
2023-05-26 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
KR20190124270A
(ko)
|
2017-03-10 |
2019-11-04 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체의 생산 방법
|
BR112019019706A2
(pt)
|
2017-03-22 |
2020-04-28 |
Genentech Inc |
conjugado de anticorpo, anticorpo, composição farmacêutica, métodos para reduzir ou inibir angiogênese e para tratar um distúrbio ocular
|
CA3055985A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
TW202400231A
(zh)
|
2017-03-28 |
2024-01-01 |
美商建南德克公司 |
治療神經退化性疾病之方法
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
CN110573528B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性tnf受容体に対する二重特異性抗原結合分子
|
RU2019134462A
(ru)
|
2017-04-03 |
2021-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Антитела, связывающиеся с steap-1
|
CN117003887A
(zh)
|
2017-04-03 |
2023-11-07 |
豪夫迈·罗氏有限公司 |
抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
CN110402255B
(zh)
|
2017-04-04 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
|
BR112019019821A2
(pt)
|
2017-04-05 |
2020-04-22 |
Hoffmann La Roche |
anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico
|
IL268620B2
(en)
|
2017-04-05 |
2024-04-01 |
Hoffmann La Roche |
Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
|
EP3615572A1
(en)
|
2017-04-27 |
2020-03-04 |
Tesaro Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
WO2018213097A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
EP3625258A1
(en)
|
2017-05-16 |
2020-03-25 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
AU2018310985A1
(en)
|
2017-08-03 |
2019-11-07 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
HUE062436T2
(hu)
|
2017-08-03 |
2023-11-28 |
Alector Llc |
Anti-trem2 antitestek és alkalmazási módszereik
|
EP3665197A2
(en)
|
2017-08-11 |
2020-06-17 |
H. Hoffnabb-La Roche Ag |
Anti-cd8 antibodies and uses thereof
|
IL253984A0
(en)
|
2017-08-14 |
2017-09-28 |
Yeda Res & Dev |
Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
|
CN111511762A
(zh)
|
2017-08-21 |
2020-08-07 |
天演药业公司 |
抗cd137分子及其用途
|
BR112020003459A2
(pt)
|
2017-08-21 |
2020-08-25 |
Adagene Inc. |
bibliotecas, animal não humano, fago, cadeia leve de anticorpo, anticorpos, métodos para preparar uma biblioteca, para produzir uma biblioteca de anticorpos e para gerar um anticorpo biespecífico e kit
|
KR20200038996A
(ko)
|
2017-08-21 |
2020-04-14 |
아다진 인크. |
동적 인간 중쇄 항체 라이브러리
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
JP2020534811A
(ja)
|
2017-09-08 |
2020-12-03 |
マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. |
Fc領域を含有する条件的に活性化された結合部分
|
TW201936634A
(zh)
|
2017-09-29 |
2019-09-16 |
日商中外製藥股份有限公司 |
具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
WO2019086497A2
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted ox40 agonists
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Compボディ−多価標的結合物質
|
CN111182944B
(zh)
|
2017-11-01 |
2022-11-22 |
豪夫迈·罗氏有限公司 |
双特异性2+1 Contorsbody
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
PL3704146T3
(pl)
|
2017-11-01 |
2022-03-07 |
F. Hoffmann-La Roche Ag |
Przeciwciało Contorsbody trifab
|
MX2020005562A
(es)
|
2017-11-30 |
2020-08-20 |
Genentech Inc |
Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1.
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
TWI805665B
(zh)
|
2017-12-21 |
2023-06-21 |
瑞士商赫孚孟拉羅股份公司 |
結合hla-a2/wt1之抗體
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
EP3731864A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche SA |
Anti-vegf antibodies and methods of use
|
EA202091650A1
(ru)
|
2018-01-05 |
2020-12-02 |
Ас Иммьюн Са |
Неправильно свернутые tdp-43-связывающие молекулы
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
WO2019148026A1
(en)
|
2018-01-26 |
2019-08-01 |
Genentech, Inc. |
Il-22 fc fusion proteins and methods of use
|
RS63812B1
(sr)
|
2018-01-26 |
2023-01-31 |
Hoffmann La Roche |
Il-22 fc kompozicije i postupci primene
|
CN111971301A
(zh)
|
2018-01-31 |
2020-11-20 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
AU2019214183B2
(en)
|
2018-02-01 |
2022-04-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
WO2019158645A1
(en)
|
2018-02-14 |
2019-08-22 |
Abba Therapeutics Ag |
Anti-human pd-l2 antibodies
|
CN111757751A
(zh)
|
2018-02-21 |
2020-10-09 |
豪夫迈·罗氏有限公司 |
用于使用IL-22 Fc融合蛋白的治疗的剂量方案
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
EP3533459A1
(en)
|
2018-03-02 |
2019-09-04 |
Diaccurate |
Anti-pla2-gib antibodies and the uses thereof
|
EP3533460A1
(en)
|
2018-03-02 |
2019-09-04 |
Diaccurate |
Therapeutic anti-spla2-gib antibodies and the uses thereof
|
AU2019232523A1
(en)
|
2018-03-05 |
2020-09-03 |
Etablissement Francais Du Sang |
Recombinant single chain immunoglobulins
|
TW202003561A
(zh)
|
2018-03-13 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
EP3765489A1
(en)
|
2018-03-13 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
CA3094235A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
FR3080621B1
(fr)
|
2018-04-26 |
2022-12-09 |
Univ Limoges |
Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde
|
EP3787678A1
(en)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
AR115418A1
(es)
|
2018-05-25 |
2021-01-13 |
Alector Llc |
ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
|
US20210238308A1
(en)
|
2018-06-04 |
2021-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
AU2019282778A1
(en)
|
2018-06-08 |
2020-12-10 |
Alector Llc |
Anti-Siglec-7 antibodies and methods of use thereof
|
MA52968A
(fr)
|
2018-06-23 |
2021-04-28 |
Hoffmann La Roche |
Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
|
SG11202010990TA
(en)
|
2018-06-29 |
2020-12-30 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
EP3818082A1
(en)
|
2018-07-04 |
2021-05-12 |
F. Hoffmann-La Roche AG |
Novel bispecific agonistic 4-1bb antigen binding molecules
|
PE20210186A1
(es)
|
2018-07-13 |
2021-02-02 |
Alector Llc |
Anticuerpos anti-sortilina y metodos para su uso
|
SG11202013193XA
(en)
|
2018-07-17 |
2021-02-25 |
Humabs Biomed Sa |
Antibodies against campylobacter species
|
KR20210032488A
(ko)
|
2018-07-20 |
2021-03-24 |
서피스 온콜로지, 인크. |
항-cd112r 조성물 및 방법
|
BR112021001451A2
(pt)
|
2018-07-27 |
2021-04-27 |
Alector Llc |
anticorpos monoclonais anti-siglec-5 isolados, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, composição farmacêutica e métodos para induzir ou promover a sobrevida, para diminuir a atividade, para diminuir os níveis celulares, para induzir a produção de espécies reativas, para induzir a formação de neutrophil extracellular trap (net), para induzir a ativação de neutrófilos, para atenuar um ou mais neutrófilos imunossuprimidos e para aumentar a atividade de fagocitose
|
SG11202101152QA
(en)
|
2018-08-03 |
2021-03-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
KR20210042936A
(ko)
|
2018-08-08 |
2021-04-20 |
제넨테크, 인크. |
단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도
|
EA202190451A1
(ru)
|
2018-08-10 |
2021-07-13 |
Чугаи Сейяку Кабусики Кайся |
Анти-cd137 антигенсвязывающие молекулы и их применение
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
SG11202101552SA
(en)
|
2018-08-31 |
2021-03-30 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
EP3857230B1
(en)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
UA126188C2
(uk)
|
2018-10-01 |
2022-08-25 |
Ф. Хоффманн-Ля Рош Аг |
Біспецифічна антигензв'язувальна молекула, яка містить домен зв'язування з fap та домен зв'язування з сd40
|
JP2022511396A
(ja)
|
2018-10-01 |
2022-01-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd40への三価結合を伴う二重特異性抗原結合分子
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CA3115110A1
(en)
|
2018-10-24 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
ES2961791T3
(es)
|
2018-12-19 |
2024-03-13 |
Humabs Biomed Sa |
Anticuerpos que neutralizan el virus de la hepatitis B y usos de los mismos
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
EP3898683A1
(en)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
EP3898673A1
(en)
|
2018-12-21 |
2021-10-27 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
PE20211696A1
(es)
|
2018-12-21 |
2021-09-01 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor
|
JP2022515543A
(ja)
|
2018-12-30 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
抗ウサギcd19抗体および使用方法
|
EP3914291A2
(en)
|
2019-01-22 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Immunoglobulin a antibodies and methods of production and use
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
CN114390938A
(zh)
|
2019-03-05 |
2022-04-22 |
武田药品工业有限公司 |
受约束的条件性活化的结合蛋白
|
EP3934761A1
(en)
|
2019-03-05 |
2022-01-12 |
Takeda Pharmaceutical Company Limited |
Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
|
MX2021010565A
(es)
|
2019-03-08 |
2021-10-13 |
Genentech Inc |
Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
|
WO2020189748A1
(ja)
|
2019-03-19 |
2020-09-24 |
中外製薬株式会社 |
Mta依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
|
CN113677403A
(zh)
|
2019-04-12 |
2021-11-19 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
CA3134522A1
(en)
|
2019-04-19 |
2020-10-22 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
CA3132275A1
(en)
|
2019-04-25 |
2020-10-29 |
Ulrich Brinkmann |
Generation of antibody-derived polypeptides by polypeptide chain exchange
|
KR20220004052A
(ko)
|
2019-04-25 |
2022-01-11 |
에프. 호프만-라 로슈 아게 |
폴리펩티드 사슬 교환에 의해 활성화된 치료용 다중특이적 폴리펩티드
|
MX2021012931A
(es)
|
2019-04-25 |
2021-11-17 |
Hoffmann La Roche |
Polipeptidos multiespecificos activables y terapeuticos con semivida extendida.
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
CA3137882A1
(en)
|
2019-05-23 |
2020-11-26 |
Tamara SEREDENINA |
Anti-tdp-43 binding molecules and uses thereof
|
US20200392229A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
AU2020304813A1
(en)
|
2019-06-26 |
2022-01-06 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding CEA and 4-1BBL
|
WO2020260326A1
(en)
|
2019-06-27 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
MX2021015193A
(es)
|
2019-06-28 |
2022-01-18 |
Hoffmann La Roche |
Metodo para la produccion de un anticuerpo.
|
TW202115115A
(zh)
|
2019-07-02 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
免疫結合物
|
CR20220049A
(es)
|
2019-07-10 |
2022-03-02 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión a claudina-6 y usos de las mismas
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
BR112022001460A2
(pt)
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Gprc5dに結合する抗体
|
US11667699B2
(en)
|
2019-07-31 |
2023-06-06 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
JP7181438B2
(ja)
|
2019-08-06 |
2022-11-30 |
アプリノイア セラピューティクス リミテッド |
病理学的タウ種に結合する抗体及びその使用
|
WO2021030633A1
(en)
|
2019-08-13 |
2021-02-18 |
Elpis Biopharmaceuticals |
Engineered interleukin-2 receptor beta agonists
|
EP3786180A1
(en)
|
2019-08-27 |
2021-03-03 |
Diaccurate |
Antibodies and the uses thereof
|
CA3148990A1
(en)
|
2019-08-29 |
2021-03-04 |
Vir Biotechnology, Inc. |
Compositions and methods for treatment of influenza a infection
|
EP4021578A1
(en)
|
2019-08-29 |
2022-07-06 |
VIR Biotechnology, Inc. |
Antibody compositions and methods for treating hepatitis b virus infection
|
CN114616250A
(zh)
|
2019-09-04 |
2022-06-10 |
豪夫迈·罗氏有限公司 |
Cd8结合剂及其用途
|
KR20220062304A
(ko)
|
2019-09-12 |
2022-05-16 |
제넨테크, 인크. |
루푸스 신장염을 치료하는 조성물과 방법
|
EP4031579A2
(en)
|
2019-09-18 |
2022-07-27 |
F. Hoffmann-La Roche AG |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
EP4036116A4
(en)
|
2019-09-27 |
2024-01-24 |
Nanjing Genscript Biotech Co Ltd |
ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF
|
CN114746119A
(zh)
|
2019-09-27 |
2022-07-12 |
詹森生物科技公司 |
抗-ceacam抗体及其用途
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
CN114945386A
(zh)
|
2019-10-18 |
2022-08-26 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
CN115551594A
(zh)
|
2019-10-24 |
2022-12-30 |
米诺陶治疗公司 |
经细胞因子修饰的嵌合抗体及其使用方法
|
MX2022005400A
(es)
|
2019-11-06 |
2022-05-24 |
Genentech Inc |
Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
|
KR20220101079A
(ko)
|
2019-11-15 |
2022-07-19 |
에프. 호프만-라 로슈 아게 |
단백질 수용액 내 가시적 입자 형성의 방지
|
JP2023506014A
(ja)
|
2019-12-12 |
2023-02-14 |
アレクトル エルエルシー |
抗cd33抗体の使用方法
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
CR20220329A
(es)
|
2019-12-13 |
2022-11-23 |
Alector Llc |
Anticuerpos anti–mertk y metodos de uso de los mismos
|
PE20221661A1
(es)
|
2019-12-18 |
2022-10-26 |
Hoffmann La Roche |
Anticuerpos anti-ccl2 biespecificos
|
CA3161390A1
(en)
|
2019-12-18 |
2021-06-24 |
Tina WEINZIERL |
Antibodies binding to hla-a2/mage-a4
|
KR20220118527A
(ko)
|
2019-12-23 |
2022-08-25 |
제넨테크, 인크. |
아포지질단백질 l1-특이적 항체 및 이용 방법
|
IL294226A
(en)
|
2019-12-27 |
2022-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibodies and their use
|
MX2022008214A
(es)
|
2020-01-09 |
2022-08-08 |
Hoffmann La Roche |
Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
US20240043489A1
(en)
|
2020-01-15 |
2024-02-08 |
Trutino Biosciences Inc. |
Cytokine Prodrugs Comprising a Cleavable Linker
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021155295A1
(en)
|
2020-01-31 |
2021-08-05 |
The Cleveland Clinic Foundation |
Anti-müllerian hormone receptor 2 antibodies and methods of use
|
JP2023512684A
(ja)
|
2020-02-03 |
2023-03-28 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Sars-cov-2に対する抗体およびそれを使用する方法
|
EP4105237A4
(en)
|
2020-02-10 |
2024-03-27 |
Shanghai Escugen Biotechnology Co Ltd |
ANTI-CLDN18.2 ANTIBODIES AND ITS USE
|
US20230096452A1
(en)
|
2020-02-10 |
2023-03-30 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
AU2021227687B2
(en)
|
2020-02-26 |
2023-02-23 |
Vir Biotechnology, Inc. |
Antibodies against SARS-CoV-2 and methods of using the same
|
MX2022011156A
(es)
|
2020-03-13 |
2022-10-13 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos.
|
US11919948B2
(en)
|
2020-03-19 |
2024-03-05 |
Genentech, Inc. |
Isoform-selective anti-TGFβ antibodies and methods of use
|
CR20220489A
(es)
|
2020-03-24 |
2022-10-31 |
Genentech Inc |
Agentes de fijación a tie2 y métodos de uso.
|
EP4126937A1
(en)
|
2020-03-31 |
2023-02-08 |
Alector LLC |
Anti-mertk antibodies and methods of use thereof
|
KR20220161375A
(ko)
|
2020-03-31 |
2022-12-06 |
추가이 세이야쿠 가부시키가이샤 |
다중 특이성 항원 결합 분자를 제조하기 위한 방법
|
US20230107644A1
(en)
|
2020-04-01 |
2023-04-06 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
EP4130732A1
(en)
|
2020-04-02 |
2023-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
WO2021211775A1
(en)
|
2020-04-14 |
2021-10-21 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
CN115916822A
(zh)
|
2020-04-24 |
2023-04-04 |
基因泰克公司 |
使用抗CD79b免疫缀合物的方法
|
TW202216757A
(zh)
|
2020-04-28 |
2022-05-01 |
美國洛克菲勒大學 |
中和性抗sars-cov-2抗體及其使用方法
|
BR112022022021A2
(pt)
|
2020-04-30 |
2022-12-13 |
Genentech Inc |
Anticorpos, ácido(s) nucleico(s), vetor, célula hospedeira, processo para produzir um anticorpo, métodos para rastrear um anticorpo, detectar kras-gdp, obter um inibidor, detectar a alquilação de kras, tratar um câncer, rastrear compostos, medir a ligação de uma proteína e medir o engajamento do alvo de um inibidor, kit, chaperona de cristalização, método de cristalização e superfície de biossensor
|
CA3177562A1
(en)
|
2020-05-03 |
2021-11-11 |
Tong Zhu |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
CA3177169A1
(en)
|
2020-05-08 |
2021-11-11 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2
|
CR20220576A
(es)
|
2020-05-11 |
2022-12-07 |
Hoffmann La Roche |
Tratamiento conjunto con pbmc modificadas y un inmunoconjugado
|
JP2023520249A
(ja)
|
2020-05-15 |
2023-05-16 |
エフ. ホフマン-ラ ロシュ アーゲー |
非経口タンパク質溶液中の可視粒子形成の防止方法
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
AU2021281417A1
(en)
|
2020-05-29 |
2022-12-08 |
23Andme, Inc. |
Anti-CD200R1 antibodies and methods of use thereof
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
TW202204396A
(zh)
|
2020-06-08 |
2022-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗hbv抗體及使用方法
|
JP2023530274A
(ja)
|
2020-06-12 |
2023-07-14 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
SARS-CoV-2感染の抗体療法
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
TW202200616A
(zh)
|
2020-06-18 |
2022-01-01 |
美商建南德克公司 |
使用抗tigit抗體及pd-1軸結合拮抗劑之治療
|
CR20220628A
(es)
|
2020-06-19 |
2023-01-24 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
CR20220604A
(es)
|
2020-06-19 |
2023-01-23 |
Hoffmann La Roche |
Anticuerpos biespecíficos para linfocitos t activados por proteasa
|
TW202216767A
(zh)
|
2020-06-19 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
與CD3及FolR1結合之抗體
|
AR122657A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Moléculas de unión al dominio fc de activación inmunitaria
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
CA3183475A1
(en)
|
2020-06-22 |
2021-12-30 |
Thomas Huber |
Anti-il-36 antibodies and methods of use thereof
|
MX2022015795A
(es)
|
2020-06-23 |
2023-01-24 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2.
|
WO2021262840A1
(en)
|
2020-06-24 |
2021-12-30 |
Vir Biotechnology, Inc. |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd3/抗cd28二重特異性抗原結合分子
|
JP2023532764A
(ja)
|
2020-07-07 |
2023-07-31 |
エフ. ホフマン-ラ ロシュ アーゲー |
治療用タンパク質製剤の安定剤としての代替界面活性剤
|
WO2022008688A1
(en)
|
2020-07-10 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
AR123001A1
(es)
|
2020-07-17 |
2022-10-19 |
Genentech Inc |
Anticuerpos anti-notch2 y métodos de uso
|
CN116249556A
(zh)
|
2020-07-21 |
2023-06-09 |
基因泰克公司 |
降解brm的抗体缀合化学诱导剂及其方法
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
JP2023536158A
(ja)
|
2020-07-31 |
2023-08-23 |
ジェネンテック, インコーポレイテッド |
抗インテグリンβ7抗体製剤及び装置
|
TW202221016A
(zh)
|
2020-08-07 |
2022-06-01 |
美商建南德克公司 |
Flt3配位體融合蛋白及使用方法
|
IL276627A
(en)
|
2020-08-10 |
2022-03-01 |
Yeda Res & Dev |
Compositions for diagnosis and treatment of coronavirus infections
|
WO2022034228A1
(en)
|
2020-08-14 |
2022-02-17 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
US20230416371A1
(en)
|
2020-08-28 |
2023-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimer fc polypeptide
|
EP4211165A1
(en)
|
2020-09-14 |
2023-07-19 |
Ichnos Sciences SA |
Antibodies that bind to il1rap and uses thereof
|
IL301503A
(en)
|
2020-09-23 |
2023-05-01 |
Yeda res & development co ltd |
Methods and preparations for the treatment of the disease caused by the corona virus
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
CN116724053A
(zh)
|
2020-09-24 |
2023-09-08 |
弗雷德哈钦森癌症中心 |
靶向sox2抗原的免疫治疗
|
JP2023545322A
(ja)
|
2020-09-28 |
2023-10-27 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Sars-cov-2に対する抗体
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022082201A1
(en)
|
2020-10-16 |
2022-04-21 |
Genentech, Inc. |
Anti-cleaved icaspase substrate antibodies and methods of use
|
CN116685325A
(zh)
|
2020-10-20 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
|
CA3192306A1
(en)
|
2020-10-20 |
2022-04-28 |
Burkhard Ludewig |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
IL302396A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
WO2022098870A1
(en)
|
2020-11-04 |
2022-05-12 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
EP4244254A1
(en)
|
2020-11-16 |
2023-09-20 |
F. Hoffmann-La Roche AG |
Combination therapy with fap-targeted cd40 agonists
|
JP2023551666A
(ja)
|
2020-11-23 |
2023-12-12 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
A型インフルエンザウイルスに対する抗体
|
TW202235105A
(zh)
|
2020-11-23 |
2022-09-16 |
美商維爾生物科技股份有限公司 |
抗流感抗體及其組合
|
TW202229329A
(zh)
|
2020-11-23 |
2022-08-01 |
美商維爾生物科技股份有限公司 |
針對流感神經胺酸酶的廣泛中和抗體
|
TW202235107A
(zh)
|
2020-11-25 |
2022-09-16 |
美商維爾生物科技股份有限公司 |
結合至多種乙型冠狀病毒的抗體
|
AU2021392039A1
(en)
|
2020-12-02 |
2023-06-29 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
CR20230219A
(es)
|
2020-12-04 |
2023-07-07 |
Hoffmann La Roche |
Polipéptidos de interleucina-2 mutante dependientes del ph
|
WO2022125517A1
(en)
|
2020-12-08 |
2022-06-16 |
Vir Biotechnology, Inc. |
Antibodies and methods for treatment of influenza a infection
|
KR20230120665A
(ko)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
항-hla-g 항체 및 이의 용도
|
CA3207090A1
(en)
|
2021-01-06 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
EP4277705A1
(en)
|
2021-01-12 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
WO2022159842A1
(en)
|
2021-01-25 |
2022-07-28 |
Vir Biotechnology, Inc. |
Antibody combination therapies for sars-cov-2 infection
|
TW202245838A
(zh)
|
2021-01-26 |
2022-12-01 |
美商維爾生物科技股份有限公司 |
用於治療b型肝炎病毒感染的組成物及方法
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
EP4284422A1
(en)
|
2021-01-28 |
2023-12-06 |
Vaccinvent GmbH |
Method and means for modulating b-cell mediated immune responses
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
EP4289866A2
(en)
|
2021-02-04 |
2023-12-13 |
Genuv Inc. |
Anti-pd-1 antibody and use thereof
|
JP2024506321A
(ja)
|
2021-02-09 |
2024-02-13 |
ヒューマブス・バイオメッド・ソシエテ・アノニム |
呼吸器合胞体ウイルスおよび他のパラミクソウイルスに対する抗体およびその使用方法
|
EP4301418A1
(en)
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
JP2024511970A
(ja)
|
2021-03-15 |
2024-03-18 |
ジェネンテック, インコーポレイテッド |
ループス腎炎の治療の組成物及び方法
|
CA3213295A1
(en)
|
2021-03-17 |
2022-09-22 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
CN116981696A
(zh)
|
2021-03-18 |
2023-10-31 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
JP2024511610A
(ja)
|
2021-03-23 |
2024-03-14 |
アレクトル エルエルシー |
コロナウイルス感染の治療及び予防のための抗tmem106b抗体
|
CN117157312A
(zh)
|
2021-03-30 |
2023-12-01 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的多肽
|
EP4067376A1
(en)
|
2021-03-30 |
2022-10-05 |
Diaccurate |
Anti-pla2g1b monoclonal antibodies and uses thereof
|
EP4317175A1
(en)
|
2021-03-31 |
2024-02-07 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Truncated taci polypeptide and fusion protein and use thereof
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
EP4339207A1
(en)
|
2021-05-12 |
2024-03-20 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2022237882A1
(zh)
|
2021-05-14 |
2022-11-17 |
江苏恒瑞医药股份有限公司 |
一种抗原结合分子
|
AR125855A1
(es)
|
2021-05-14 |
2023-08-16 |
Genentech Inc |
Agonistas de trem2
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
EP4347642A2
(en)
|
2021-05-24 |
2024-04-10 |
VIR Biotechnology, Inc. |
Engineered polypeptides
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
US20230036592A1
(en)
|
2021-06-03 |
2023-02-02 |
Surface Oncology, Inc. |
Methods of treating cancer with an anti-cd39 antibody and pembrolizumab
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
KR20240019109A
(ko)
|
2021-06-09 |
2024-02-14 |
에프. 호프만-라 로슈 아게 |
암의 치료에 이용하기 위한 특정 braf 억제제(패러독스 브레이크) 및 pd-1 축 결합 길항제의 조합물
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2022266659A1
(en)
|
2021-06-17 |
2022-12-22 |
Genentech, Inc. |
Anti-ubiquitination antibodies and methods of use
|
EP4355775A1
(en)
|
2021-06-18 |
2024-04-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-ccl2 antibodies
|
WO2022270612A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ctla-4抗体の使用
|
KR20240024213A
(ko)
|
2021-06-25 |
2024-02-23 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체
|
KR20240032959A
(ko)
|
2021-07-14 |
2024-03-12 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Hgfr 및 egfr에 특이적으로 결합하는 항원-결합 분자, 및 이의 약학적 용도
|
TW202309097A
(zh)
|
2021-07-14 |
2023-03-01 |
美商建南德克公司 |
抗c-c模體趨化因子受體8(ccr8)抗體及其使用方法
|
CA3226100A1
(en)
|
2021-07-21 |
2023-01-26 |
Phillip S. KIM |
Linker polypeptides
|
CN117730102A
(zh)
|
2021-07-22 |
2024-03-19 |
豪夫迈·罗氏有限公司 |
异二聚体Fc结构域抗体
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
WO2023021055A1
(en)
|
2021-08-19 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Multivalent anti-variant fc-region antibodies and methods of use
|
TW202328177A
(zh)
|
2021-08-27 |
2023-07-16 |
美商建南德克公司 |
治療tau病理學之方法
|
TW202315895A
(zh)
|
2021-08-27 |
2023-04-16 |
瑞士商休曼生物醫藥股份公司 |
經工程化的組成物
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
CA3230613A1
(en)
|
2021-09-01 |
2023-03-09 |
Daren J. AUSTIN |
Antibody therapies for sars-cov-2 infection in pediatric subjects
|
WO2023034871A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
High concentration antibody therapies for sars-cov-2 infection
|
WO2023036815A1
(en)
|
2021-09-07 |
2023-03-16 |
Etablissement Francais Du Sang |
Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
|
WO2023039442A1
(en)
|
2021-09-08 |
2023-03-16 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibody combination therapies for sars-cov-2 infection
|
CA3232472A1
(en)
|
2021-09-23 |
2023-03-30 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-klb antibodies and uses
|
WO2023051798A1
(zh)
|
2021-09-30 |
2023-04-06 |
江苏恒瑞医药股份有限公司 |
抗il23抗体融合蛋白及用途
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
CA3234731A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023081818A1
(en)
|
2021-11-05 |
2023-05-11 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
AR127692A1
(es)
|
2021-11-16 |
2024-02-21 |
Ac Immune Sa |
Anticuerpos anti-asc para uso en tratamientos antiinflamatorios
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023156549A1
(en)
|
2022-02-16 |
2023-08-24 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
TW202346365A
(zh)
|
2022-03-23 |
2023-12-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及化學療法之組合治療
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
TW202402794A
(zh)
|
2022-03-28 |
2024-01-16 |
瑞士商赫孚孟拉羅股份公司 |
經改良的folr1蛋白酶可活化之t細胞雙特異性抗體
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023201256A1
(en)
|
2022-04-12 |
2023-10-19 |
Vir Biotechnology, Inc. |
High dose antibody therapies for sars-cov-2 infection
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023201291A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of mosunetuzumab and methods of use
|
US20230406930A1
(en)
|
2022-04-13 |
2023-12-21 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023230445A2
(en)
|
2022-05-23 |
2023-11-30 |
Humabs Biomed Sa |
Broadly neutralizing antibodies against influenza neuraminidase
|
WO2023230448A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Combination immunotherapy for influenza
|
WO2023230439A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237706A2
(en)
|
2022-06-08 |
2023-12-14 |
Institute For Research In Biomedicine (Irb) |
Cross-specific antibodies, uses and methods for discovery thereof
|
WO2023245078A1
(en)
|
2022-06-15 |
2023-12-21 |
Humabs Biomed Sa |
Anti-parvovirus antibodies and uses thereof
|
WO2024006472A1
(en)
|
2022-06-30 |
2024-01-04 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026411A1
(en)
|
2022-07-27 |
2024-02-01 |
Humabs Biomed Sa |
Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024038198A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038183A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038193A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024052922A1
(en)
|
2022-09-11 |
2024-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-klk4 antibodies and uses thereof
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|